NGCS
$TVGN Here is the actual breakdown of the share structure and why the real float remains tightly locked up 🔒
1️⃣ The 50M CEO Lock-Up: Out of the 68.68M total shares listed in the recent S-3 filing, 50M shares belong to CEO Dr. Ryan Saadi’s performance award. They are strictly locked and unvested until Tevogen hits $1 BILLION in revenue by 2031. Zero dilution
2️⃣ Institutional Price Floor ($7.40 - $8.00): The newly registered 1.03M shares belong to The Patel from their debt-to-equity
3️⃣ Ultra-Low Tradeable Float: Once you strip out insider holdings and restricted locks, the actual freely tradeable public float sits under 1M shares (~841k)
4️⃣ ATM Intact & Baby Shelf Protected: The $50M ATM facility remains untouched and strictly capped by SEC Baby Shelf rules, while the $28.6M credit facility is secured through May 2029.
The float is locked, insiders are aligned with $1B in revenue, and coiled for the definitive LOI closings (HRK Healthcare / CRO / MSO). 🚀 #BioTech #AI
1
:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Flarge_sealsq_stock_market_representative_resized_b05435011f.jpg)
:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Flarge_stock_down_resized_901c19c371.jpg)